Skip to main content

Table 2 Synergism studies between cisplatin and NVP-BEZ235

From: Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38

BEZ235 [nM]
cisplatin [μM] 30 40 50 60 70
1 a a 0.74 0.69 0.76
2 0.76 0.70 0.71 0.60 0.66
3 0.76 0.59 0.61 0.60 0.64
5 0.71 0.63 0.62 0.61 0.67
7 0.70 0.59 0.61 0.60 0.67
  1. afraction affected <0.2